U.S. Markets closed

Daiichi Sankyo Company, Limited -- Moody's: Daiichi Sankyo's collaboration with AstraZeneca is positive for the former's oncology franchise

Moody's Investors Service says that Daiichi Sankyo Company, Limited's (A2 stable) announced collaboration with AstraZeneca PLC (A3 stable) on Daiichi Sankyo's trastuzumab deruxtecan (DS-8201) breast cancer drug is beneficial to the growth of the Japanese company's oncology franchise. On 29 March, Daiichi Sankyo announced the collaboration with AstraZeneca on the global development and commercialization of DS-8201, the most promising drug in Daiichi Sankyo's pipeline.